v3.25.4

Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenues	$ 116,588	$ 105,757
Operating expenses:
Cost of revenues	5,416	3,884
Selling and marketing	65,179	57,511
Research and development	13,698	12,024
General and administrative	20,804	16,109
Loss on disposal of assets, net	4	66
Total operating expenses	105,101	89,594
Income from operations	11,487	16,163
Other income (expenses):
Interest income, net	1,747	1,547
Other expense, net	(1,505)	(1,659)
Change in fair value of warrant liability	2,707	7,167
Total income before income taxes	14,436	23,218
Provision for income taxes	(4,556)	(5,320)
Net income	9,880	17,898
Net income attributable to noncontrolling interest	4,853	5,813
Net income attributable to common stockholders	$ 5,027	$ 12,085
Net income per share attributable to common stockholders, basic	$ 0.06	$ 0.14
Net income per share attributable to common stockholders, diluted	$ 0.02	$ 0.05
Weighted average shares used in calculating net income per share attributable to common stockholders, basic	89,344,622	85,094,948
Weighted average shares used in calculating net income per share attributable to common stockholders, diluted	103,180,037	102,293,526
Other comprehensive income:
Net income	$ 9,880	$ 17,898
Foreign currency translation adjustments	2,636	(1,460)
Comprehensive income from operations	12,516	16,438
Net income attributable to noncontrolling interest	4,853	5,813
Foreign currency translation adjustments attributable to noncontrolling interest	818	(507)
Comprehensive income attributable to noncontrolling interest	5,671	5,306
Comprehensive income attributable to common stockholders	$ 6,845	$ 11,132

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

GYRE THERAPEUTICS, INC. 10-K